CDTX vs SPGI · rev $1.3M vs P/E 27, rev $15.34B
Cidara Therapeutics Inc (CDTX) versus S&P Global Inc (SPGI) — a side-by-side from cached financials, not a winner call.
Cidara Therapeutics Inc (CDTX) is a biotechnology company listed on US.
S&P Global Inc (SPGI) is a financial data & stock exchanges company listed on NYSE.
Latest reported CDTX revenue for 2024-12-31 was $1.3M. Net income was -$169.8M. Revenue was down 94.5% from 2023-12-31 to 2024-12-31. CDTX currently screens at market cap $6.96B.
Latest reported SPGI revenue for 2025-12-31 was $15.34B. Net income was $4.47B. Revenue was up 7.9% from 2024-12-31 to 2025-12-31. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
CDTX currently screens at market cap $6.96B. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
Not investment advice. Open the CDTX and SPGI stock pages for the full models.
Not investment advice.